Abstract: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n (I) wherein M, T, B and n ore as defined in claim 1.

Abstract: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n (I) wherein M, T, B and n ore as defined in claim 1.

Abstract: The present invention relates to mucin glycoconjugates, and to a process of producing mucin glycoconjugates. It relates to the biological, pharmaceutical and medical applications thereof. The invention notably provides mucin glycoconjugates which do not require a protein carrier, such as KHL, to induce an immune response (anti-Tn IgG).

Abstract: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n(I) wherein M, T, B and n are as defined in claim 1.

Abstract: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n(I) wherein M, T, B and n are as defined in claim 1.

Abstract: The present invention relates to mucin glycoconjugates, and to a process of producing mucin glycoconjugates. It relates to the biological, pharmaceutical and medical applications thereof. The invention notably provides mucin glycoconjugates which do not require a protein carrier, such as KHL, to induce an immune response (anti-Tn IgG).

Abstract: The invention of the present application relates to a method for obtaining antibodies directed against a carbohydrate moiety contained in a carbohydrate peptide conjugate, by administering to a subject a composition containing a carbohydrate peptide conjugate and collecting the antibodies directed against the said carbohydrate moiety from a serum previously obtained from the subject.

Abstract: The present invention relates to a glycoconjugate, a composition and vaccine comprising the same and to the use thereof for enhancing the immune response in cancer therapy wherein the induction of a humoral or a cellular immune response is sought. The invention also relates to a diagnosis kit and to a method for the diagnosis of a cancer.

Abstract: A carbohydrate peptide conjugate comprising a carrier comprising a dendrimeric poly-Lysine enabling multipic epitopes to be covalently attached thereto, at least one peptide comprising one T epitope or several identical or different T epitopes, at least one carbohydrate moiety, or a derivative thereof, containing B epitope, provided it is not a sialoside, or several identical or different epitopes. Use of this conjugate for inducing immune response.

Abstract: A carbohydrate peptide conjugate comprising:

Abstract: A carbohydrate peptide conjugate containing: (i) a carrier containing a dendrimeric poly-lysine enabling multiple epitopes to be covalently attached thereto, (ii) at least one peptide containing one T epitope or several identical or different T-epitopes, (iii) at least one carbohydrate moiety which is tumor antigen, or a derivative thereof, containing a B epitope, provided it is not a sialoside, or several identical or different epitopes, wherein said conjugate containing at least 3-lysines and up to 15 lysine covalently linked to one another, and wherein: (a) to the NH2 and of at least two lysine residues is bound at least one carbohydrate residue being not a sialoside, optionally substituted and containing an epitope and wherein the peptide containing one T epitope is covalently bound to the end of said carbohydrate which induces immune responses.

Abstract: A carbohydrate peptide conjugate comprising:

Abstract: Attempts to generate modified viral pseudo-particles that are capable of stably incorporating heterologous antigenic determinants has encountered a number of difficulties including inhibition of pseudo-particle formation following epitope insertion and failure of the epitope to retain its native configuration. The present invention is directed toward recombinant viral pseudo-particles of the family Parvoviridae that stably encode heterologous epitopes. Hybrid virus-like particles (VLP) were prepared by self-assembly of a modified porcine parvovirus (PPV) VP2 capsid protein carrying a CD8+ or CD4+ T cell epitope in the amino terminus. Immunization of mice with hybrid pseudo-particles carrying a lymphocytic choriomeningitis virus (LCMV) nucleoprotein CTL epitope, without adjuvant, induced strong cytotoxic T lymphocyte (CTL) responses against both peptide-coated- or virus-infected-target cells.